Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.95 Million USD | -24.23% |
| 2022 | 3.89 Million USD | 39.04% |
| 2021 | 2.8 Million USD | -15.14% |
| 2020 | 3.3 Million USD | -36.11% |
| 2019 | 5.16 Million USD | 128.17% |
| 2018 | 2.26 Million USD | 47.75% |
| 2017 | 1.53 Million USD | -61.5% |
| 2016 | 3.98 Million USD | -21.97% |
| 2015 | 5.1 Million USD | 868.3% |
| 2014 | 527 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 1.88 Million USD | 163.17% |
| 2007 | 716.53 Thousand USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 2.68 Million USD | 23.82% |
| 2002 | 2.16 Million USD | 25.28% |
| 2001 | 1.73 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.25 Million USD | 10.23% |
| 2024 Q2 | 2.95 Million USD | -9.31% |
| 2023 Q2 | 3.4 Million USD | -6.43% |
| 2023 Q3 | 3.08 Million USD | -9.52% |
| 2023 FY | 2.95 Million USD | -24.23% |
| 2023 Q4 | 2.95 Million USD | -4.16% |
| 2023 Q1 | 3.63 Million USD | -6.62% |
| 2022 Q3 | 2.8 Million USD | 33.33% |
| 2022 FY | 3.89 Million USD | 39.04% |
| 2022 Q2 | 2.1 Million USD | -17.87% |
| 2022 Q1 | 2.55 Million USD | -8.74% |
| 2022 Q4 | 3.89 Million USD | 39.14% |
| 2021 FY | 2.8 Million USD | -15.14% |
| 2021 Q1 | 3.55 Million USD | -7.14% |
| 2021 Q4 | 2.8 Million USD | 3.13% |
| 2021 Q3 | 2.71 Million USD | -6.34% |
| 2021 Q2 | 2.9 Million USD | -18.33% |
| 2020 FY | 3.3 Million USD | -36.11% |
| 2020 Q3 | 2.84 Million USD | -44.34% |
| 2020 Q2 | 5.1 Million USD | 5.57% |
| 2020 Q1 | 4.83 Million USD | -6.48% |
| 2020 Q4 | 3.82 Million USD | 34.68% |
| 2019 Q3 | 5.31 Million USD | 8.99% |
| 2019 Q4 | 5.16 Million USD | -2.71% |
| 2019 Q2 | 4.87 Million USD | -4.26% |
| 2019 FY | 5.16 Million USD | 128.17% |
| 2019 Q1 | 5.09 Million USD | 124.77% |
| 2018 Q2 | 1.37 Million USD | -3.91% |
| 2018 Q4 | 2.26 Million USD | 38.79% |
| 2018 Q3 | 1.63 Million USD | 18.6% |
| 2018 Q1 | 1.43 Million USD | -6.59% |
| 2018 FY | 2.26 Million USD | 47.75% |
| 2017 Q1 | 3.71 Million USD | -6.83% |
| 2017 Q2 | 4.07 Million USD | 9.84% |
| 2017 Q3 | 1.44 Million USD | -64.66% |
| 2017 Q4 | 1.53 Million USD | 6.46% |
| 2017 FY | 1.53 Million USD | -61.5% |
| 2016 Q2 | 2.65 Million USD | -57.06% |
| 2016 FY | 3.98 Million USD | -21.97% |
| 2016 Q1 | 6.17 Million USD | 20.93% |
| 2016 Q3 | 3.18 Million USD | 20.34% |
| 2016 Q4 | 3.98 Million USD | 24.87% |
| 2015 Q4 | 5.1 Million USD | 7.36% |
| 2015 FY | 5.1 Million USD | 868.3% |
| 2015 Q1 | 805.68 Thousand USD | 52.88% |
| 2015 Q2 | 3.63 Million USD | 350.55% |
| 2015 Q3 | 4.75 Million USD | 30.94% |
| 2014 Q3 | 105.55 Thousand USD | -8.22% |
| 2014 FY | 527 Thousand USD | 0.0% |
| 2014 Q2 | 115 Thousand USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | 527 Thousand USD | 399.29% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | -100.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q1 | 3.51 Million USD | 86.64% |
| 2009 Q2 | 3.31 Million USD | -5.84% |
| 2009 Q3 | 135.45 Thousand USD | -95.91% |
| 2008 Q2 | 1.92 Million USD | 47.18% |
| 2008 FY | 1.88 Million USD | 163.17% |
| 2008 Q1 | 1.3 Million USD | 82.45% |
| 2008 Q4 | 1.88 Million USD | -31.26% |
| 2008 Q3 | 2.74 Million USD | 42.57% |
| 2007 Q1 | 100 Thousand USD | 0.0% |
| 2007 FY | 716.53 Thousand USD | 0.0% |
| 2007 Q4 | 716.53 Thousand USD | 102.45% |
| 2007 Q3 | 353.93 Thousand USD | 15.52% |
| 2007 Q2 | 306.37 Thousand USD | 206.37% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | -100.0% |
| 2003 FY | 2.68 Million USD | 23.82% |
| 2003 Q2 | 2.24 Million USD | -2.55% |
| 2003 Q4 | 2.68 Million USD | 9.42% |
| 2003 Q1 | 2.3 Million USD | 6.45% |
| 2003 Q3 | 2.45 Million USD | 9.08% |
| 2002 FY | 2.16 Million USD | 25.28% |
| 2002 Q2 | 1.92 Million USD | 5.67% |
| 2002 Q1 | 1.82 Million USD | 5.4% |
| 2002 Q3 | 2.04 Million USD | 5.93% |
| 2002 Q4 | 2.16 Million USD | 6.19% |
| 2001 Q3 | 3.35 Million USD | 570.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | 1.73 Million USD | 0.0% |
| 2001 Q4 | 1.73 Million USD | -48.32% |
| 2001 Q2 | 500 Thousand USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -496.364% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -977.372% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 97.548% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -39.707% |
| Azitra, Inc. | 885.94 Thousand USD | -233.203% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -7280.185% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -132.682% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 59.204% |
| CEL-SCI Corporation | 13.57 Million USD | 78.249% |
| iBio, Inc. | 4.46 Million USD | 33.812% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 16.985% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | -21.267% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | -7.737% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -844.027% |
| BiomX Inc. | 15.09 Million USD | 80.44% |
| BiomX Inc. | 15.09 Million USD | 80.44% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 88.768% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -400.053% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 78.977% |